Immune checkpoint blocking agents such as the Programmed cell death-1 (PD1)-antagonist pembrolizumab have been approved for the treatment of metastatic melanoma . Owing to its mechanism of action, this drug restores tumour-specific T-cell response and may induce various types of immune-related adverse events (irAEs) . Haematological toxicities are rare, and cytopenia of autoimmune origin remain exceptional. Herein, we report the occurrence of successive haematologic adverse events in a patient treated with pembrolizumab for a metastatic melanoma including an immune-mediated pure red cell aplasia (PRCA) followed by an immune thrombocytopaenia (IT).
A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia
Leggi l'articolo originale